News | Graduate School of Medical Sciences

COVID-19 May Trigger Hyperglycemia and Worsen Disease by Harming Fat Cells

COVID-19 may bring high risks of severe disease and death in many patients by disrupting key metabolic signals and thereby triggering hyperglycemia, according to a new study from researchers at Weill Cornell Medicine and NewYork-Presbyterian.

In the study, reported Sept. 15 in Cell Metabolism, the researchers found that hyperglycemia—having high blood sugar levels—is common in hospitalized COVID-19 patients and...

Antibody-Producing B Cells May be "Predestined" for their Fates

The master regulator behind the development of antibody-producing cells has been identified in a study by investigators at Weill Cornell Medicine. The findings provide new insight into the inner workings of the immune system and may help understand how tissues develop and how certain cancers arise.

The study, published Sept. 23 in Nature Immunology, combined computational analyses with advanced molecular biology and genomic techniques to identify a protein called Oct2 as the key...

Weill Cornell Advances TB Research with Support from NIH

Tuberculosis (TB) is a wily old killer, one of the deadliest infectious diseases in history and one of the few that naturally infects only humans. Researchers at Weill Cornell Medicine have been pursuing treatments for tuberculosis caused by Mycobacterium tuberculosis (Mtb) since the 1950s, and the program continues to excel at explaining TB’s mysteries and pushing toward more effective therapies.

Currently, Weill Cornell Medicine investigators are leading or...

Weill Cornell Medicine Awarded $28.5 Million NIH Grant to Lead HIV Cure Research

Weill Cornell Medicine has been awarded a five-year, $28.5 million Martin Delaney Collaboratory grant from the National Institutes of Health to lead a multi-institutional effort aimed at finding a cure for HIV.

HIV remains a top global health concern, with nearly 38 million people worldwide infected with the virus, and 770,000 deaths from AIDS in 2018, according to the World Health Organization. While modern...

Commentary: Multisector Research Collaborative Aims to Advance Tuberculosis Treatment

A better understanding of the biology of tuberculosis (TB) infection and improved drug combinations for the disease are two areas of research in which the TB Drug Accelerator (TBDA) has made strides since its inception a decade ago, according to a commentary whose authors include three Weill Cornell Medicine investigators and an investigator at Cornell University’s Ithaca campus who participate in the collaborative network.

TB is an infectious disease that typically affects the lungs...

Office of Diversity and Inclusion Named Diversity Champion

Weill Cornell Medicine’s Office of Diversity and Inclusion has been recognized as a Diversity Champion by Crain’s New York Business as part of its first annual Excellence in Diversity and Inclusion Awards, announced July 15.

The Diversity Champion award recognizes organizations in all industries that have committed to a diverse workforce and have programs or initiatives advancing the promotion of diversity in the workplace. Weill Cornell Medicine won in the large-company category.

...

multicolor dots representing different cell types

Research Suggests How Tumors Evolve to Become Aggressive Form of Prostate Cancer

The genetic changes that underlie an especially lethal type of prostate cancer have been revealed in a new study by investigators at Weill Cornell Medicine. Learning more about what causes this type of cancer, called neuroendocrine prostate cancer (NEPC), could lead to new approaches for treating it.

Most early-stage prostate cancers require male hormones (androgens) like testosterone to grow. However, as they advance, they may evolve into castration-resistant prostate cancer (CRPC), a...

A group of people at a ceremony launch event.

Weill Cornell Medicine Launches $1.5 Billion We’re Changing Medicine Campaign with More Than $750 Million in Gifts

Video of We're Changing Medicine - Campaign Launch Event

NEW YORK (June 17, 2021) — Building on a legacy of groundbreaking advances in medicine and science, Weill Cornell Medicine today launched an ambitious $1.5 billion campaign—with more than $750 million already raised—that will harness emerging biomedical innovations to bring exemplary care to patients and create enduring change in medicine.

The We’re Changing Medicine campaign is the...

COVID-19 Virus Linked to Pancreatic Cell Identity Shift

SARS-CoV-2, the virus causing the global COVID-19 pandemic, can infect human pancreatic cells and alter their physiology, according to research from Weill Cornell Medicine and NewYork-Presbyterian investigators. Though the results come from analyses of autopsy samples and cultured cells and don't prove a direct causal relationship, they dovetail with clinical reports of glucose control problems in COVID-19 patients, suggesting a new dimension of disease development for a virus that has...

1 of 19
next ›